Cargando…

Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice

Purpose. We successfully developed recombinant human interferon alpha-2b (rhIFN-α2b) and mutein forms through the site-directed mutagenesis technique. The mutein forms were developed by substituting cysteins at positions 2 and 99 with aspartic acids. The potential adverse effects of these rhIFN-α2bs...

Descripción completa

Detalles Bibliográficos
Autores principales: Rachmawati, H., Merika, A., Ningrum, R. A., Anggadiredja, K., Retnoningrum, D. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659462/
https://www.ncbi.nlm.nih.gov/pubmed/23738335
http://dx.doi.org/10.1155/2013/943687
_version_ 1782270442930700288
author Rachmawati, H.
Merika, A.
Ningrum, R. A.
Anggadiredja, K.
Retnoningrum, D. S.
author_facet Rachmawati, H.
Merika, A.
Ningrum, R. A.
Anggadiredja, K.
Retnoningrum, D. S.
author_sort Rachmawati, H.
collection PubMed
description Purpose. We successfully developed recombinant human interferon alpha-2b (rhIFN-α2b) and mutein forms through the site-directed mutagenesis technique. The mutein forms were developed by substituting cysteins at positions 2 and 99 with aspartic acids. The potential adverse effects of these rhIFN-α2bs were assessed by acute and subchronic studies. Methods. In the acute study, rhIFN-α2bs were subcutaneously administered to mice at a single dose of 97.5 μg/kg, 975 μg/kg, and 9.75 mg/kg BW and were observed for 14 days. In the subchronic study, single dose of 1.95 μg/kg and 19.5 μg/kg, respectively, was given subcutaneously every 3 days for 45 days. Results. No death as well as abnormality in body weight, behavior, presentation of main organs, and value of plasma SGPT and SGOT was observed. Wild type and mutein rhIFN-α2bs did not show significant adverse effects at dose up to 9.75 mg/kg BW. Administration of these rhIFN-α2bs given repeatedly did not induce any adverse effect. Conclusion. These results suggest that our rhIFN-α2bs are safe. However, further study is still needed to clarify the safety issue before use in clinical trial.
format Online
Article
Text
id pubmed-3659462
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36594622013-06-04 Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice Rachmawati, H. Merika, A. Ningrum, R. A. Anggadiredja, K. Retnoningrum, D. S. Biomed Res Int Research Article Purpose. We successfully developed recombinant human interferon alpha-2b (rhIFN-α2b) and mutein forms through the site-directed mutagenesis technique. The mutein forms were developed by substituting cysteins at positions 2 and 99 with aspartic acids. The potential adverse effects of these rhIFN-α2bs were assessed by acute and subchronic studies. Methods. In the acute study, rhIFN-α2bs were subcutaneously administered to mice at a single dose of 97.5 μg/kg, 975 μg/kg, and 9.75 mg/kg BW and were observed for 14 days. In the subchronic study, single dose of 1.95 μg/kg and 19.5 μg/kg, respectively, was given subcutaneously every 3 days for 45 days. Results. No death as well as abnormality in body weight, behavior, presentation of main organs, and value of plasma SGPT and SGOT was observed. Wild type and mutein rhIFN-α2bs did not show significant adverse effects at dose up to 9.75 mg/kg BW. Administration of these rhIFN-α2bs given repeatedly did not induce any adverse effect. Conclusion. These results suggest that our rhIFN-α2bs are safe. However, further study is still needed to clarify the safety issue before use in clinical trial. Hindawi Publishing Corporation 2013 2013-05-02 /pmc/articles/PMC3659462/ /pubmed/23738335 http://dx.doi.org/10.1155/2013/943687 Text en Copyright © 2013 H. Rachmawati et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rachmawati, H.
Merika, A.
Ningrum, R. A.
Anggadiredja, K.
Retnoningrum, D. S.
Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice
title Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice
title_full Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice
title_fullStr Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice
title_full_unstemmed Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice
title_short Evaluation of Adverse Effects of Mutein Forms of Recombinant Human Interferon Alpha-2b in Female Swiss Webster Mice
title_sort evaluation of adverse effects of mutein forms of recombinant human interferon alpha-2b in female swiss webster mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659462/
https://www.ncbi.nlm.nih.gov/pubmed/23738335
http://dx.doi.org/10.1155/2013/943687
work_keys_str_mv AT rachmawatih evaluationofadverseeffectsofmuteinformsofrecombinanthumaninterferonalpha2binfemaleswisswebstermice
AT merikaa evaluationofadverseeffectsofmuteinformsofrecombinanthumaninterferonalpha2binfemaleswisswebstermice
AT ningrumra evaluationofadverseeffectsofmuteinformsofrecombinanthumaninterferonalpha2binfemaleswisswebstermice
AT anggadiredjak evaluationofadverseeffectsofmuteinformsofrecombinanthumaninterferonalpha2binfemaleswisswebstermice
AT retnoningrumds evaluationofadverseeffectsofmuteinformsofrecombinanthumaninterferonalpha2binfemaleswisswebstermice